new_0222_0423|CYT|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0423|CYT|Long Name|1|1|Cyteir Therapeutics Inc Total Current Assets (Quarterly) (USD)|Cyteir Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Cyteir Therapeutics Inc Inventories (Quarterly) (USD)|Cyteir Therapeutics Inc Net PP&E (Quarterly) (USD)|Cyteir Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Cyteir Therapeutics Inc Total Liabilities (Quarterly) (USD)|Cyteir Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Cyteir Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Cyteir Therapeutics Inc Total Deposits (Quarterly) (USD)|Cyteir Therapeutics Inc Book Value (Quarterly) (USD)|Cyteir Therapeutics Inc Retained Earnings (Quarterly) (USD)|Cyteir Therapeutics Inc Treasury Stock (Quarterly) (USD)|Cyteir Therapeutics Inc EV to Revenues|Cyteir Therapeutics Inc EV to Earnings|Cyteir Therapeutics Inc EV to Free Cash Flow|Cyteir Therapeutics Inc EV to Assets (Quarterly)|Cyteir Therapeutics Inc PS Ratio|Cyteir Therapeutics Inc PE Ratio|Cyteir Therapeutics Inc Price to Book Value|Cyteir Therapeutics Inc PEG Ratio|Cyteir Therapeutics Inc Debt to Equity Ratio|Cyteir Therapeutics Inc Dividend Yield|Cyteir Therapeutics Inc Shareholder Yield (TTM)|Cyteir Therapeutics Inc Percent of Shares Outstanding Short|Cyteir Therapeutics Inc Total Receivables (Quarterly) (USD)|Cyteir Therapeutics Inc Total Payables (Quarterly) (USD)|Cyteir Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Cyteir Therapeutics Inc Return on Invested Capital|Cyteir Therapeutics Inc Quality Ratio Score|Cyteir Therapeutics Inc Momentum Score|Cyteir Therapeutics Inc Beta (1Y)|Cyteir Therapeutics Inc Sustainable Growth Rate (TTM)|Cyteir Therapeutics Inc Institutional Investor Ownership Percentage|Cyteir Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Cyteir Therapeutics Inc Total Employees (Annual)|Cyteir Therapeutics Inc EPS Diluted (Quarterly) (USD)|Cyteir Therapeutics Inc SG&A Expense (Quarterly) (USD)|Cyteir Therapeutics Inc Shares Outstanding|Cyteir Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Cyteir Therapeutics Inc Ordinary Shares Number (Quarterly)|Cyteir Therapeutics Inc Payout Ratio|Cyteir Therapeutics Inc Quick Ratio (Quarterly)|Cyteir Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Cyteir Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Cyteir Therapeutics Inc Effective Tax Rate (TTM)|Cyteir Therapeutics Inc Return on Equity|Cyteir Therapeutics Inc Net Income (TTM) (USD)|Cyteir Therapeutics Inc Revenue (TTM) (USD)|Cyteir Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Cyteir Therapeutics Inc Revenue (Quarterly) (USD)|Cyteir Therapeutics Inc Gross Profit (Quarterly) (USD)|Cyteir Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Cyteir Therapeutics Inc Net Income (Quarterly) (USD)|Cyteir Therapeutics Inc Net Interest Income (Quarterly) (USD)|Cyteir Therapeutics Inc Price (USD)|Cyteir Therapeutics Inc Total Return Price (USD)|Cyteir Therapeutics Inc Enterprise Value (USD)|Cyteir Therapeutics Inc 30-Day Average Daily Volume|Cyteir Therapeutics Inc 1 Year Price Returns (Daily)|Cyteir Therapeutics Inc Short Interest|Cyteir Therapeutics Inc PE Ratio (Forward)|Cyteir Therapeutics Inc PE Ratio (Forward 1y)|Cyteir Therapeutics Inc PS Ratio (Forward)|Cyteir Therapeutics Inc PS Ratio (Forward 1y)|Cyteir Therapeutics Inc Quarterly EPS Estimates (USD)|Cyteir Therapeutics Inc Quarterly Revenue Estimates (USD)|Cyteir Therapeutics Inc Quarterly EPS Surprise|Cyteir Therapeutics Inc Quarterly Revenue Surprise|Cyteir Therapeutics Inc Quarterly Actual EPS (USD)|Cyteir Therapeutics Inc Quarterly Actual Revenue (USD)|Cyteir Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Cyteir Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Cyteir Therapeutics Inc Price Target (USD)|Cyteir Therapeutics Inc Consensus Recommendation|Cyteir Therapeutics Inc Price Target Num Estimates|Cyteir Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Cyteir Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Cyteir Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Cyteir Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Cyteir Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Cyteir Therapeutics Inc Land and Improvements (Quarterly) (USD)|Cyteir Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Cyteir Therapeutics Inc Other Properties (Quarterly) (USD)|Cyteir Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0423|CYT|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0423|CYT||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0423|CYT||5|5|91|91|0|91|0|91|91|91|0|91|91|0|0|0|1.44117647059|0|0|0|1.43827160494|0|0|1.44117647059|0|15.3571428571|90|91|91|0|0|0|0|0|31|91.3333333333|0|91.3333333333|91.3333333333|29.8|0|91|0|0|91.3333333333|91.4|0|0|91|0|0|0|0|91.3333333333|91.3333333333|0|1.44117647059|1.44117647059|1.44117647059|1.43971631206|0|15.3571428571|0|0|0|0|92|91.5|92|0|92|92|42|52.5|30|17.5|30|19.0909090909|23.3333333333|91.3333333333|91.3333333333|0|0|0|0|91
new_0222_0423|CYT||6|6|3|3|0|3|0|3|3|3|0|3|3|0|0|0|170|0|0|0|162|0|0|170|0|14|1|3|3|0|0|0|0|0|2|6|0|6|6|5|0|3|0|0|6|5|0|0|3|0|0|0|0|6|6|0|170|170|170|141|0|14|0|0|0|0|2|6|1|0|1|1|5|4|7|12|7|11|9|6|6|0|0|0|0|3
new_0222_0423|CYT||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0423|CYT|202003|202003|202003||||||||||||||||||||||||||||||||||23.8903||-0.2482|1.009||||||-0.2482|||||||||-5.929|-5.929|||||||||||||||||||||||||5.001|0.067|||||
new_0222_0423|CYT|202006|202006|202006||||||||||||||||||||||||||||||||||23.8903||-0.1883|0.875||||||-0.1883|0||||||||-4.498|-4.498|||||||||||||||||||||||||3.633|0.082|||||
new_0222_0423|CYT|202009|202009|202009||||||||||||||||||||||||||||||||||23.8903||-0.2108|0.831||||||-0.2108|0||||||||-5.036|-5.036|||||||||||||||||||||||||4.214|0.107|||||
new_0222_0423|CYT|202012|202012|202012|12.131|10.938||1.287||61.766|3.137|58.629||-48.031|-49.927||||||||||||||0.063|1.689|0.002|||||||23.8903||-0.2244|1.463|||34.4666|||-0.2244||||-20.823|||||-5.36|-5.36|||||||||||||||||||||||||3.917|0.095|||||0.694
new_0222_0423|CYT|202103|202103|202103|85.385|84.195||1.432||142.293|4.264|138.029||-54.504|-57.239||||||||||||||0.059|2.805|0.002|||||||23.8903||-0.31|1.724|||34.4666|||-0.31||||-22.206|||||-7.312|-7.312|||||||||||||||||||||||||5.613|0.103|||||0.942
new_0222_0423|CYT|202105|202103|202103|||||||||||||||||||||||||||||||||||31|||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0423|CYT|202106|202106|202106|200.305|198.637||1.492||8.198|7.444|0.754||193.855|-68.534||||-22.3019||||3.7649|||0||0.0931||3.512|0.034||||||78.4356|2.3379||-4.83|2.422|34.1049||34.1049|||-4.83|-121.627|||-29.003|||||-11.295|-11.295||21.4|21.4|531.2079|||31739|||||-1.4604|0|-230.7313||-4.83|0||||||||8.886|0.111|||||1.115
new_0222_0423|CYT|202107|202106|202106|||||||||||||||-19.2234||||3.3867|||0||1.8792|||||||||81.8364||||||||||||||||||||||19.25|19.25|457.8823|201293.4||640887|||||||||||0|0|31.5|1.5|4|-1.5946|-1.7509|||||||
new_0222_0423|CYT|202108|202106|202106|||||||||||||||-19.9932||||3.4812|||0||3.751|||||||||80.8225|||||35.3697|||||||||||||||||19.08|19.08|476.2169|109650.2333||1326723|||||||||||0|0|31.5|1.5|4|-2.3426|-1.9016|||||||
new_0222_0423|CYT|202109|202109|202109|204.219|199.822||1.634||8.267|7.53|0.737||197.842|-80.238||||-12.8859||||3.1141|||0||6.9471||3.276|0.035|||||||35.0629||-0.33|3.547|35.1055||35.1055|||-0.33|-14.494|||-35.671|||||-11.704|-11.704||17.55|17.55|416.2795|184291.8||2438834|||||-0.3511|0|6.0204||-0.33|0||||||||8.205|0.125|||||1.382
new_0222_0423|CYT|202110|202109|202109|||||||||||||||-13.2771||||3.178|||0||6.0209|||||||||||||||||||||||||||||||17.91|17.91|428.9175|83737.9||2113661||||||||||||||||||||||||
new_0222_0423|CYT|202111|202109|202109|||||||||||||||-12.0009||||2.9696|||0||6.3703||||||||||||||35.3709|||||||||||||||||16.61|16.61|387.6886|62278.2||2253226|||||||||||0|0|31.5|1.5|4|-2.025|-1.836|||||||
new_0222_0423|CYT|202112|202112|202112|||||||||||||||-6.2636||||2.0328|||0||6.75|||||||||||||||||||||||||||||||11.37|11.37|202.3451|73488.2667||2387540|||||-0.3857|0|||||0|||||-2.046||||||||
new_0222_0423|CYT|202201|202112|202112|||||||||||||||-0.4715||||1.087|||0||7.0454|||||||||||||||||||||||||||||||6.08|6.08|15.2331|124069.3667||2492036|||||||||||||26.75|1.5|4|-1.8385|-2.1345|||||||
new_0222_0423|CYT|202202|202112|202112|||||||||||||||-0.3183||||1.062|||0|||||||||||||||||||||||||||||||||5.94|5.94|10.2811|131512.8667|||||||||||||0|0|24.6|1.4|5|-1.7708|-2.0258|||||||
new_0222_0423|CYT|202203|202203|202203||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||
new_0222_0423|CYT|202206|202206|202206||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||
new_0222_0423|CYT|202209|202209|202209||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||
new_0222_0423|CYT|202212|202212|202212||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||